In a study from Mayo Clinic, scientists found that for high-risk patients with mild-to-moderate COVID-19 during the Omicron epoch, bebtelovimab seems to be a reliable treatment option.
They examined 3,607 high-risk patients to examine the effectiveness of bebtelovimab in real-world settings. A total of 2,833 patients received bebtelovimab and 774 received nirmatrelvir-ritonavir.
The researchers found that compared with nirmatrelvir-ritonavir, bebtelovimab was used more often for the treatment of COVID-19 among older patients, immunosuppressed patients, and those with multiple comorbidities.
The rates of progression to severe disease by 30 days after treatment were not strongly different after bebtelovimab versus nirmatrelvir-ritonavir treatment (1.4 versus 1.2 percent).
The rate of admission to the intensive care unit was comparable between the groups (0.5 and 0.3 percent for those receiving bebtelovimab and nirmatrelvir-ritonavir treatment, respectively).
The team says this study gives them confidence that bebtelovimab is reliable for the treatment of high-risk patients during this Omicron epoch and gives people another tool in the effort against COVID-19.
In February, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant.
The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
For more information about COVID, please see recent studies about drugs that can block multiple COVID-19 variants, and results showing aspirin, common anti-inflammatory drug may prevent COVID-19 deaths.
The study was conducted by Raymund R. Razonable et al and published in the Journal of Infectious Diseases.
Copyright © 2022 Knowridge Science Report. All rights reserved.